Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

pembrolizumab 83Carboplatin 78Magnetic Resonance Spectroscopy 68Specimen Handling 66Cisplatin 63Paclitaxel 58Gemcitabine 50Docetaxel 40Dexamethasone 38Cyclophosphamide 37Oxaliplatin 35Fluorouracil 35Radiotherapy 34Leucovorin 34Doxorubicin 34Radiation 33Pemetrexed 33Bevacizumab 31Capecitabine 30durvalumab 27Etoposide 27Vincristine 26Rituximab 26Nivolumab 24Prednisone 23Letrozole 23Irinotecan 23Taxes 22Lenalidomide 22Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Goserelin × 30 days × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

Phase 3 Active not recruiting
608 enrolled 18 charts
Breast

Breast Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡